| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy (NCT04963153) | National Cancer Institute (NCI) | 2022-07-07 |
| Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy (NCT04637594) | Alliance for Clinical Trials in Oncology | 2022-05-27 |
| Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma (NCT05154994) | University of Utah | 2022-01-14 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib (NCT05052372) | xCures | 2021-11-21 |
| A Study of NX-1607 in Adults With Advanced Malignancies (NCT05107674) | Nurix Therapeutics, Inc. | 2021-09-29 |
| Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer (NCT04878029) | Emory University | 2021-07-23 |
| Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer (NCT04639245) | Fred Hutchinson Cancer Center | 2021-07-19 |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (NCT04579224) | National Cancer Institute (NCI) | 2021-06-28 |
| Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma (NCT04701918) | Massachusetts General Hospital | 2021-06-04 |
| Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma (NCT04848519) | Emory University | 2021-05-20 |
| Sacituzumab Govitecan Plus EV in Metastatic UC (NCT04724018) | Dana-Farber Cancer Institute | 2021-05-20 |
| Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients (NCT04863885) | H. Lee Moffitt Cancer Center and Research Institute | 2021-04-30 |
| A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer (NCT04839510) | Shanghai Miracogen Inc. | 2021-04-20 |
| Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial (NCT04693377) | M.D. Anderson Cancer Center | 2021-03-16 |
| A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing (NCT06129084) | Bernie Eigl | 2021-01-11 |
| Urine Omics Predicting IO Therapy Responses in mUC Patients (NCT04641936) | National Taiwan University Hospital | 2020-12-17 |
| DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers (NCT04388852) | M.D. Anderson Cancer Center | 2020-08-20 |
| A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma (NCT04486781) | Vasgene Therapeutics, Inc | 2020-08-14 |
| Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) (NCT04003610) | Incyte Corporation | 2020-05-14 |
| A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients (NCT04383067) | Sheba Medical Center | 2020-05-12 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744) | Mayo Clinic | 2020-02-13 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (NCT04200963) | Ikena Oncology | 2019-12-18 |
| Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma (NCT03854474) | National Cancer Institute (NCI) | 2019-11-18 |
| An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy (NCT04623502) | University of Texas Southwestern Medical Center | 2019-09-30 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (NCT03513952) | National Cancer Institute (NCI) | 2019-06-05 |
| Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer (NCT03744793) | M.D. Anderson Cancer Center | 2019-04-11 |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (NCT03682289) | Rahul Aggarwal | 2019-01-17 |
| Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma (NCT03464734) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2019-01-16 |
| Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (NCT03534804) | University of Utah | 2018-09-18 |
| Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (NCT03590054) | Rahul Aggarwal | 2018-08-20 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (NCT03397394) | pharmaand GmbH | 2018-06-01 |
| Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations (NCT03047213) | National Cancer Institute (NCI) | 2017-08-24 |
| Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer (NCT02693717) | M.D. Anderson Cancer Center | 2017-05-09 |
| A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers (NCT03115801) | Weill Medical College of Cornell University | 2016-11-01 |
| Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery (NCT02420847) | M.D. Anderson Cancer Center | 2015-07-03 |
| Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer (NCT02351739) | Acerta Pharma BV | 2015-04-01 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (NCT01552434) | M.D. Anderson Cancer Center | 2012-10-16 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer (NCT00942331) | National Cancer Institute (NCI) | 2009-07-15 |